Leerink Partnrs Issues Negative Forecast for IRWD Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities research analysts at Leerink Partnrs cut their Q4 2024 earnings per share estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst F. Khurshid now anticipates that the biotechnology company will post earnings per share of $0.08 for the quarter, down from their previous forecast of $0.09. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q3 2025 earnings at $0.07 EPS, FY2025 earnings at $0.06 EPS and FY2026 earnings at $0.36 EPS.

Several other equities analysts have also issued reports on IRWD. JMP Securities lowered their price target on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Thursday. StockNews.com lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Finally, Craig Hallum cut their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, January 22nd. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.67.

Ironwood Pharmaceuticals Trading Down 38.2 %

Shares of Ironwood Pharmaceuticals stock opened at $2.30 on Friday. Ironwood Pharmaceuticals has a 1-year low of $2.25 and a 1-year high of $15.70. The firm has a fifty day simple moving average of $3.90 and a 200-day simple moving average of $4.50. The stock has a market capitalization of $368.07 million, a price-to-earnings ratio of -76.67 and a beta of 0.34.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The company had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The firm’s revenue was down 19.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.12 earnings per share.

Insider Activity at Ironwood Pharmaceuticals

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the sale, the chief financial officer now directly owns 309,572 shares of the company’s stock, valued at approximately $1,263,053.76. This represents a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 12.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. KBC Group NV grew its stake in shares of Ironwood Pharmaceuticals by 59.3% during the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,198 shares during the last quarter. Journey Strategic Wealth LLC acquired a new position in Ironwood Pharmaceuticals during the 4th quarter worth $45,000. SG Americas Securities LLC bought a new position in Ironwood Pharmaceuticals in the 4th quarter valued at $53,000. Diversified Trust Co acquired a new stake in shares of Ironwood Pharmaceuticals in the 3rd quarter valued at $52,000. Finally, Wolverine Trading LLC bought a new stake in shares of Ironwood Pharmaceuticals during the third quarter worth $51,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.